JPH0568267B2 - - Google Patents
Info
- Publication number
- JPH0568267B2 JPH0568267B2 JP50011085A JP50011085A JPH0568267B2 JP H0568267 B2 JPH0568267 B2 JP H0568267B2 JP 50011085 A JP50011085 A JP 50011085A JP 50011085 A JP50011085 A JP 50011085A JP H0568267 B2 JPH0568267 B2 JP H0568267B2
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- pulses
- concentration
- series
- free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 353
- 102000004877 Insulin Human genes 0.000 claims description 176
- 108090001061 Insulin Proteins 0.000 claims description 176
- 229940125396 insulin Drugs 0.000 claims description 176
- 150000001720 carbohydrates Chemical class 0.000 claims description 32
- 238000012545 processing Methods 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 235000012054 meals Nutrition 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 44
- 239000008103 glucose Substances 0.000 description 44
- 235000014633 carbohydrates Nutrition 0.000 description 37
- 238000001802 infusion Methods 0.000 description 28
- 239000000446 fuel Substances 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 230000002503 metabolic effect Effects 0.000 description 11
- 230000037406 food intake Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 210000003240 portal vein Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 210000002989 hepatic vein Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- -1 sutucarose Chemical compound 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56243583A | 1983-12-16 | 1983-12-16 | |
| US562435 | 1983-12-16 | ||
| US678511 | 1984-12-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61500710A JPS61500710A (ja) | 1986-04-17 |
| JPH0568267B2 true JPH0568267B2 (fr) | 1993-09-28 |
Family
ID=24246272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50011085A Granted JPS61500710A (ja) | 1983-12-16 | 1984-12-10 | インシュリン供給アルゴリズム |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61500710A (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008272503A (ja) * | 2002-03-29 | 2008-11-13 | Thomas Takemi Aoki | インスリンを注入する装置 |
| JP2014512368A (ja) * | 2011-04-12 | 2014-05-22 | トーマス タケミ アオキ | 代謝活性化療法の術前使用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007047351A1 (de) * | 2007-10-02 | 2009-04-09 | B. Braun Melsungen Ag | System und Verfahren zur Überwachung und Regelung von Blutglukosewerten |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2758467C2 (de) * | 1977-12-28 | 1985-04-04 | Siemens AG, 1000 Berlin und 8000 München | Vorrichtung zur vorprogrammierbaren Infusion von Flüssigkeiten |
| DE2758368C2 (de) * | 1977-12-28 | 1985-10-17 | Siemens AG, 1000 Berlin und 8000 München | Vorrichtung zur vorprogrammierbaren Infusion von Flüssigkeiten |
| DE3018833A1 (de) * | 1979-05-23 | 1981-11-26 | SIEMENS AG AAAAA, 1000 Berlin und 8000 München | Steuervorrichtung fuer implantierbare geraete, insbesondere implantierbare infusionsgeraete zur dosierbaren abgabe von fluessigkeiten |
| JPS5628765A (en) * | 1979-08-17 | 1981-03-20 | Nikkiso Co Ltd | Artificial pancreas |
| CA1154345A (fr) * | 1980-03-07 | 1983-09-27 | Elton M. Tucker | Appareil pour perfusion controlee et methode d'utilisation |
| JPS57211361A (en) * | 1981-06-23 | 1982-12-25 | Terumo Corp | Liquid injecting apparatus |
-
1984
- 1984-12-10 JP JP50011085A patent/JPS61500710A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008272503A (ja) * | 2002-03-29 | 2008-11-13 | Thomas Takemi Aoki | インスリンを注入する装置 |
| JP4733164B2 (ja) * | 2002-03-29 | 2011-07-27 | タケミ アオキ トーマス | インスリンを注入する装置 |
| JP2014512368A (ja) * | 2011-04-12 | 2014-05-22 | トーマス タケミ アオキ | 代謝活性化療法の術前使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61500710A (ja) | 1986-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826810A (en) | System and method for treating animal body tissues to improve the dietary fuel processing capabilities thereof | |
| US4863896A (en) | Diabetic control by combined insulin forms | |
| Genuth et al. | Control of hyperglycemia in adult diabetics by pulsed insulin delivery | |
| Nathan et al. | Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients | |
| US20050137522A1 (en) | System for infusing insulin to a subject to improve impaired hepatic glucose processing | |
| US20060122098A1 (en) | System for infusing insulin to a subject to imporve impaired total body tissue glucose processing | |
| US4761287A (en) | Diabetes control by serotonin | |
| Sherwin et al. | Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump | |
| Mathews et al. | Midazolam sedation following open heart surgery | |
| EP0165973B1 (fr) | Algorithme d'administration d'insuline | |
| KITABCHI et al. | Effect of hydrocortisone and corticotropin on glucose-induced insulin and proinsulin secretion in man | |
| Hanna et al. | A portable system for continuous intravenous insulin delivery: characteristics and results in diabetic patients | |
| JPH0568267B2 (fr) | ||
| CA2480572C (fr) | Dispositif de perfusion d'insuline | |
| LERNER | The augmentation effect of secretin on the insulin responses to known stimuli: specificity for glucose | |
| Molnar et al. | Low-dosage continuous insulin infusion for diabetic coma | |
| Bergman et al. | Insulin pump therapy improves blood glucose control during hyperalimentation | |
| US7682351B2 (en) | Method for infusing insulin to a subject to improve impaired hepatic glucose processing | |
| Woodruff et al. | Avoidance of surgical hyperglycemia in diabetic patients | |
| JP4733164B2 (ja) | インスリンを注入する装置 | |
| Nathan | Management of insulin-dependent diabetes mellitus | |
| CA1328401C (fr) | Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique | |
| Bonner | Insulin infusion therapy: Potential benefits and risks | |
| Sasaki et al. | School zyxwvutsrqponmlkj | |
| Sasaki et al. | Multiple Insulin Injections in Adolescent Diabetics Using a Pen‐Type Syringe |